LONDON (The Deal) -- The U.K.'s AstraZeneca (AZN) said on Tuesday it wants to almost double revenue to at least $45 billion by 2023 as it launched its defense against Pfizer (PFE) and its unwanted 63.1 billion pounds ($107.2 billion) bid.
The London pharmaceuticals company insisted it was headed back to a growth trajectory after patent expiries weighed on 2013 revenue and earnings. In February it reported 2013 revenue of $25.7 billion, a decline of 6%, with operating profit from its core business down 25%, at $8.4 billion. AstraZeneca on Tuesday predicted 2017 revenue would be "broadly in line" with the 2013 level.
"From 2017 to 2023 AstraZeneca is targeting strong and consistent revenue growth leading to annual revenues of greater than $45 billion by 2023. Operating leverage is expected to result in core earnings growth in excess of revenue growth during this period," the company added.
As it brought forward the anticipated timing of certain Phase II and Phase III trials, it also said it sees peak sales for pipeline products of about $63 billion, or $23 billion after adjusting for risk.
"AstraZeneca is completing its transformation, and now has the right size, focus and team to deliver on one of the most exciting pipelines in the pharmaceutical industry," said CEO Pascal Soriot in a statement.
Chairman Leif Johansson added that its independent strategy will provide " benefits that should fully accrue to AstraZeneca's shareholders."
AstraZeneca rejected a sweetened 5,000 pence-per-share, stock-heavy proposal from the New York maker of Viagra on Friday, arguing that it was both way too low and motivated by so-called tax inversion -- Pfizer wants to change its tax domicile to the U.K. to benefit from the country's lower corporate tax rate.